Expression of MicroRNA-21 in Chronic Lymphoproliferative Disorders: A Cross-Sectional Study from India
Abstract: This cross-sectional study evaluated the expression of microRNA-21 (miRNA-21) in patients newly diagnosed with chronic lymphoproliferative disorders (CLPD) at a tertiary hospital in Delhi, India, between April 2023 and April 2024. A total of 26 patients were included and miRNA-21 levels were measured using quantitative PCR. Although overall miRNA-21 expression was elevated in CLPD compared to standard values, statistical significance was observed only in patients with Hodgkin and Non-Hodgkin lymphomas. No significant correlation was found between miRNA-21 expression and clinical staging systems, including Rai, Ann Arbor, and ISS. These findings suggest a potential role for miRNA-21 in lymphoproliferative diagnostics, warranting further studies with larger sample sizes for validation.
Keywords: miRNA-21, chronic lymphoproliferative disorders, lymphoma, cancer biomarker
How to Cite?: Dr. Rahul Yadav, Dr. Sunita Aggarwal, Dr. Binita Goswami, Dr. Sandeep Garg, Dr. Harpreet Singh, Dr. Pradeep Kumar, Dr. Soumia M, "Expression of MicroRNA-21 in Chronic Lymphoproliferative Disorders: A Cross-Sectional Study from India", Volume 14 Issue 5, May 2025, International Journal of Science and Research (IJSR), Pages: 287-292, https://www.ijsr.net/getabstract.php?paperid=SR25503170434, DOI: https://dx.doi.org/10.21275/SR25503170434